24.03.2017
Biotest AG DE0005227235
DGAP-News: Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)
DGAP-News: Biotest AG / Key word(s): Alliance
Biotest AG: ImmunoGen has elected not to exercise its late stage
co-development option for the US-Market with Biotest's antibody-drug
conjugate (BT-062)
24.03.2017 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
ImmunoGen has elected not to exercise its late stage co-development option
for the US-Market with Biotest's antibody-drug conjugate (BT-062)
- License agreement with ImmunoGen will continue
Dreieich, 24 March 2017. Since 2006 a collaboration and licensing agreement
between Biotest and ImmunoGen, Inc., MA (USA) (ImmunoGen) is in place for
the use of ImmunoGen's antibody-drug conjugate (ADC) linker and payload
technology used with Biotest's development-stage compound Indatuximab
Ravtansine (BT-062).
ImmunoGen notified Biotest that they have elected not to exercise a late
stage co-development option provided for in the cooperation agreement. For a
payment of USD 15 million, ImmunoGen would have opted in to share half of
the development and marketing of Indatuximab Ravtansine (BT-062) in the US
market. The license agreement with ImmunoGen regarding the use of its linker
and payload technology continues unchanged.
The Phase I/IIa study (Study 983) is investigating Indatuximab Ravtansine
(BT-062) in combination with lenalidomide or pomalidomide and dexamethasone
in patients with multiple myeloma who have not been responding (any more) to
previous treatments. Multiple myeloma is a malignant hematologic disease and
despite new treatment options patients very often relapse. Biotest presented
new clinical data derived from an ongoing combination study with BT-062 in
December 2016 at the annual meeting of the American Society of Hematology
(ASH). A phase I/II study (study 989) with Indatuximab Ravtansine (BT-062)
for the treatment of solid tumors (breast cancer and bladder cancer) is
currently being evaluated.
About Indatuximab Ravtansine (BT-062)
Indatuximab Ravtansine (BT-062) is an antibody-drug conjugate (ADC)
consisting of a monoclonal antibody and a highly potent cytotoxic maytansine
derivative (DM4) using the ADC technology developed by ImmunoGen, Inc. The
antibody binds specifically to the antigen CD138, which is over-expressed on
multiple myeloma cells and a variety of solid tumors.
Once the conjugate is internalized into the target cell, the DM4 is released
from the targeting molecule, thereby releasing it in its fully-potent state.
This combination of high efficacy and specificity with low systemic toxicity
sets BT-062 apart from most therapies currently used to treat multiple
myeloma.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.
---------------------------------------------------------------------------
24.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
557735 24.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3